Program

To view the program from the 5th Global Forum on TB Vaccines, click on the “Details” button for the sessions you wish to view.

Click here to download the 5th Global Forum program and abstract book.

Click here to read the 5th Global Forum meeting report, published in Tuberculosis

Tuesday, 20 February 2018

10:30 – 12:15

Shahjehan

Opening Session

Details

Co-Chairs: Danilo Casimiro, former Chief Scientific Officer, Aeras (USA) | Soumya Swaminathan, former Director-General, Indian Council of Medical Research (India) | David Lewinsohn, Chair, Stop TB Partnership Working Group on New TB Vaccines (USA) | Nick Drager, Executive Director, TuBerculosis Vaccine Initiative (Netherlands)

Overview of the TB epidemic globally and in India (video)
Soumya Swaminathan, Deputy Director General of Programmes, World Health Organization (Switzerland)
Civil society perspective on the need for new TB vaccines (video)
Blessina Kumar, Global Coalition of TB Activists (India)
Access and affordability for new TB vaccines (video)
Hendrik Bekedam, World Health Organization (WHO) Representative to India, WHO Country Office (India)
The potential public health impact of new TB vaccines (video)
Richard White, Professor, London School of Hygiene and Tropical Medicine and Director, TB Modelling and Analysis Consortium (UK)
Partnerships and collaboration in TB vaccine R&D (video)
Renu Swarup, Senior Advisor, Department of Biotechnology, Ministry of Science & Technology (India)
India’s commitment to end TB (video)
Sunil Khaparde, Deputy Director General (TB), Ministry of Health & Family Welfare, Government of India (India)

12:15 - 13:00

Shahjehan

Keynote Address

Details

13:00 – 14:00

Rani Bagh Lawn

Lunch

14:00 – 16:00

Shahjehan

Plenary Session 1: Increasing Probability of Success and Maximizing Impact

Details

Co-Chairs: Ann Ginsberg, Aeras (USA) | Gagandeep Kang, Translational Health Science and Technology Institute (India)

Vaccine strategies to address drug-resistant tuberculosis
Gavin Churchyard, The Aurum Institute (South Africa)
Decision-making in TB vaccine development: the stage-gate process
Georges Thiry, Joint Aeras/Tuberculosis Vaccine Initiative Working Group on Stage-Gates (France)
Can biomarkers advance the development of new TB vaccines?
Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK)
Human TB challenge – you can do that?
Eric Rubin, Harvard T.H. Chan School of Public Health (USA)
Enriching cohorts for smaller, quicker, more efficient TB vaccine studies
Dereck Tait, Aeras (South Africa)
Presented by Ann Ginsberg (Aeras)

16:15 – 17:45

Roshanara

Poster Discussion 1: Basic Vaccine Concepts and Correlates of Protective Immunity

Details

Facilitators: David Lewinsohn, Oregon Health & Science University (USA) | Vinay Kumar Nandicoori, National Institute of Immunology (India)

Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) exacerbates TB infection after aerosol challenge in mice – implications for host-directed therapy
Rasmus Mortensen, Statens Serum Institute (Denmark)
Deciphering the role of VapBC TA modules in virulence and pathogenesis of Mycobacterium tuberculosis
Sakshi Agarwal, Translational Health Science and Technology Institute (India)
Mycobacterium tuberculosis hbhA and mtp deletion elicits unique canonical pathways during early infection in THP-1 differentiated macrophages
Suventha Moodley, University of KwaZula-Natal (South Africa)
Targeting ClpB abrogates stress tolerance in Mycobacterium tuberculosis and hence its growth and infectivity
Prajna Tripathi, National Institute of Immunology (India)
Circulating HLA-DR+IFNγhiIL-17hiCD4+T effectors resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis
Asma Ahmed, Indian Institute of Science (India)
PPM, a novel Mycobacterium tuberculosis (Mtb) antigen: a candidate for vaccine development to prevent progression to tuberculosis
Chaouki Benabdessalem, Institut Pasteur de Tunis (Tunisia)
Evaluation of the immunogenicity of a promising vaccine regime to identify immune correlates of protection
Nawamin Pinpathomrat, University of Oxford (UK)
Demonstration of a correlation between the in vitro direct mycobacterial growth inhibition assay (MGIA) and protection from in vivo mycobacterial challenge
Rachel Tanner, University of Oxford (UK)
Altered systemic levels of neutrophil and mast cell granular proteins in tuberculosis-diabetes co-morbidity and changes following treatment
Kadar Abbas Moideen, National Institute of Health-NIRT-International Center for Excellence in Research (India)

Sheesh Mahal

Poster Discussion 2: Diagnostics and Epidemiology

Details

Facilitators: Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK) | Jaya Tyagi, Department of Biotechnology, All India Institute of Medical Sciences (India)

Mamtaz Mahal

Poster Viewing: Novel Vaccine Concepts; Chemistry, Manufacturing and Controls

Details

Novel Vaccine Concepts

Chemistry, Manufacturing and Controls

Miniaturized fluorescence adapter for fluorescence sputum smear microscopy using bright-field microscope
Mamta Rani, IIT Delhi (India)
Presented by Pooja Singh, IIT Delhi (India)
Development of an innovative, rapid, affordable and automated system for selective enrichment, isolation and detection of MTB in sputum sample
Saumya Singh, IIT Delhi (India)
Comparison of pellicle and liquid grown BCG reference strains in standard BCG batch release assays and protection studies
Megan Fitzpatrick, Aeras (USA)

17:45 – 18:30

Rani Bagh Lawn

Networking and Refreshments

18:30 - 20:00

Shahjehan

Inaugural Ceremony

Details

Co-Chairs: Nick Drager, Executive Director, TuBerculosis Vaccine Initiate (Netherlands) | Lucica Ditiu, Executive Director, Stop TB Partnership (Switzerland)

Prevention is better than cure: A survivor story (video)
Mona Balani, Touched by TB (India)
Regional efforts to bending the curve (video)
Poonam Khetrapal Singh, WHO Regional Director for South-East Asia (India)
Translating rhetoric into action: Transforming the global TB response (video)
Soumya Swaminathan Deputy Director General of Programmes, World Health Organization (Switzerland)
Research, innovation and partnership as the pathway to success (video)
Ashutosh Sharma, Secretary, Department of Biotechnology and Department of Science and Technology, Ministry of Science & Technology (India)
India’s role in TB vaccine research (video)
Preeti Sudan, Secretary, Department of Health and Family Welfare, Government of India & Secretary, Department of Health Researcher & Director-General, Indian Council of Medical Research
India’s mission to strengthen vaccine research (video)
Anupriya Patel, Honourable Minister of State, Ministry of Health & Family Welfare (India)

20:00 – 21:30

Rani Bagh Lawn

Forum Dinner

Wednesday, 21 February 2018

9:00 - 11:00

Shahjehan

Shahjehan Plenary Session 2: Clinical Development of New TB Vaccines

Details

Co-Chairs: Souleymane Mboup, Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations (Senegal) | Sanjay Mehendale, Indian Council of Medical Research (India)

A critical juncture in tuberculosis vaccine clinical development: overview of progress
Ann M. Ginsberg, Aeras (USA)
Community engagement and Good Participatory Practice guidelines for TB vaccine research and development
Moses Zimba, Centre for Infectious Disease Research in Zambia (Zambia)
Evaluating potential vaccine(s) in preventing disease in healthy household contacts of TB patients
Kavita Singh, Multi Vaccines Development Program (India)
A new TB vaccine on the horizon
Umesh Shaligram, Serum Institute of India (India)
Presented by Prasad Kulkarni
Prevention of infection with Mycobacterium tuberculosis by H4:IC31 vaccination or BCG revaccination in healthy adolescents: results of a randomized controlled trial
Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

11:00 - 11:30

Coffee / Tea Break

11:30 - 13:00

Shahjehan

Breakout Session 1: Basic Science Research

Details

Co-chairs: Katrin Eichelberg, National Institute for Allergy and Infectious Diseases (USA) | Rajesh Gohale, National Institute of Immunology (India)

How EsxH controls host cellular responses to Mycobacterium tuberculosis?
Ekansh Mittal, Washington University School of Medicine (USA)
Elevated cyclic AMP inhibits Mycobacterium tuberculosis-stimulated T cell IFN-γ Secretion through type I protein kinase A
Buka Samten, University of Texas Health Science Center at Tyler (USA)
A TOLLIP deficiency allele, rs5743854, is associated with decreased lncRNA TOLLIP-AS1 expression, BCG-specific T-cell memory phenotypes, and increased TB susceptibility
Javeed Ali Shah, University of Washington (USA)
Pulmonary mucosal BCG vaccination shows protection of infection in a novel repeated ultra-low dose challenge model in rhesus macaques
Frank A.W. Verreck, Biomedical Primate Research Centre (Netherlands)
Memory, activation and functional profiles of Mycobacterium tuberculosis-specific CD4 T cells in recent QFT converters
Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Protein kinase G confers survival advantage to Mycobacterium tuberculosis during latency like conditions
Mehak Zahoor Khan, National Institute of Immunology (India)

Jehangir

Breakout Session 2: Clinical Research

Details

Co-chairs: Sanjay Gurunathan, Sanofi Pasteur (USA) | Randeep Guleria, All India Institute of Medical Sciences (India)

DAR-901: an inactivated whole cell NTM booster vaccine
C. Fordham von Reyn, Geisel School of Medicine at Dartmouth (USA)
A randomized, double-blind, dose-escalation clinical trial of MTBVAC compared to BCG Vaccine SSI, in newborns living in a tuberculosis endemic region
Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Clinical development of ID93+GLA-SE as a prophylactic or therapeutic vaccine for tuberculosis
Tracey Ann Day, Infectious Disease Research Institute (USA)
Use of oral inactivated Mycobacterium manresensis to reduce the risk of TB
Pere-Joan Cardona, Institut Germans Trias i Pujol (Spain)
Phase III, placebo-controlled, 2:1 randomized, double-blinded trial of tableted immunotherapeutic TB vaccine (V7) containing 10 microgram of heat-killed M. vaccae
Aldar S. Bourinbair, Immunitor LLC (Mongolia)
Randomized open phase 1 trial of TB/FLU-01L vaccine administrated intranasally or sublingually for immunotherapy of pulmonary tuberculosis
Marina Stukova, Research Institute of Influenza (Russia)

13:00 – 14:00

Rani Bagh Lawn

Lunch

14:00 – 16:00

Shahjehan

Plenary Session 3: Novel Approaches to TB Vaccine Research & Development

Details

Co-chairs: JoAnne Flynn, University of Pittsburgh (USA) | Anil Tyagi, Guru Gobind Singh Indraprastha University (India)

The route of BCG vaccination determines immunity and protection against Mycobacterium tuberculosis infection in non-human primates
Robert Seder, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)
Vaccination following mycobacterial exposure
Thomas Scriba, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Cytomegalovirus (CMV)-based TB vaccines
Aurelio Bonavia, Vir Biotechnology (USA)
Nucleic acid vaccines for tuberculosis
Jeffrey Ulmer, GSK Vaccines (USA)
Protective potential of Mycobacterium indicus pranni (MIP) and the underlying mechanisms in animal models of tuberculosis
Sangeeta Bhaskar, National Institute of Immunology (India)

Presented by Ann Ginsberg (Aeras)

16:00 - 16:30

Coffee / Tea Break

16:30 – 18:00

Roshanara

Poster Discussion 3: Preclinical Research

Details

Facilitators: Damilo Casimiro, former Aeras (USA) | Sarala Balachandran, Council of Scientific and Industrial Research (India)

Sheesh Mahal

Poster Discussion 4: Clinical Research and Community Engagement

Details

Facilitators: Souleymane Mboup, Institut de Recherche en Sante, de Surveillance Epidemiologique et de Formations (Senegal) | Lorraine Misquith, Lawyers Collective; Global Coalition of TB Activists (India)

Immunogenicity of AERAS-404 or BCG revaccination in a prevention of established M. tuberculosis infection efficacy trial
Virginie Rozot, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Phase 1 clinical trial to evaluate the safety and immunogenicity of an adenovirus-based tuberculosis vaccine (Ad5Ag85A) administered by aerosol to healthy volunteers
Fiona Smaill, McMaster University (Canada)
Dose definition of the novel TB vaccine ID93 + GLA-SE for TB endemic countries
Adam Penn-Nicholson, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
The Toll-like receptor 4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine
Tracey Ann Day, Infectious Disease Research Institute (USA)
Safety and immunogenicity of H56:IC31 in HIV negative adults with and without latent tuberculosis(TB) infection
Angelique Kany Kany Luabeya, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Impact of implementing an effective community engagement strategy on retention rates in a Phase 2b TB disease prevention vaccine trial in South Africa, Zambia, and Kenya
Anja van der Westhuizen, Aeras Africa (South Africa)
Building a portfolio of community engagement projects to enhance TB
Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Drama as a community engagement tool to raise TB awareness
Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Leveraging libraries to raise awareness about TB on World TB Day
Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Using eCompliance for tracking patients and ensuring accuracy of data in vaccine trials
Shelly Batra, Operation ASHA (India)

Mamtaz Mahal

Poster Viewing: Basic Science Research, Biomarkers and Correlates, Epidemiology

Details

Co-Chairs: Ann Ginsberg, Aeras (USA) | Gagandeep Kang, Translational Health Science and Technology Institute (India)

Vaccine strategies to address drug-resistant tuberculosis
Gavin Churchyard, The Aurum Institute (South Africa)
Decision-making in TB vaccine development: the stage-gate process
Georges Thiry, Joint Aeras/Tuberculosis Vaccine Initiative Working Group on Stage-Gates (France)
Can biomarkers advance the development of new TB vaccines?
Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK)
Human TB challenge – you can do that?
Eric Rubin, Harvard T.H. Chan School of Public Health (USA)
Enriching cohorts for smaller, quicker, more efficient TB vaccine studies
Dereck Tait, Aeras (South Africa)
Presented by Ann Ginsberg (Aeras)

18:00 - 20:00

Shahjehan, Mumtaz Mehal, Sheesh Mahal, and Roshanara

Networking Reception and Poster Viewing

Cultural performance followed by networking and poster viewing
Posters on display in Mumtaz Mahal, Sheesh Mahal, and Roshanara
Food and drink stations will be located in Shahjehan and Roshanara

Thursday, 22 February 2018

7:15 - 8:45

Jenhangir

Satellite Session: Panel Discussion and Audience Q&A on the H4:IC31®/BCG Revaccination POI Trial Results

Organized by Sanofi Pasteur and Aeras

Details

Panel discussion featuring:

Ann Ginsberg, Aeras, USA (moderator)
Gavin Churchyard, Aurum Institute (South Africa)
Carl Dieffenbach, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)
Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
Sanjay Gurunathan, Sanofi Pasteur (USA)

Click here to view the video of the session

9:00 - 11:00

Shahjehan

Plenary Session 4: The Cutting Edge: Translating Scientific Advances into New TB Vaccines

Details

Co-Chairs: Peter Andersen, Statens Serum Institute (Denmark) | G.P. Talwar, Talwar Research Foundation (India)

Predictive biosignatures to improve tuberculosis vaccine development
Stefan H.E. Kaufmann, Max Planck Institute of Infection Biology (Germany)
Harnessing the power of innate immunity in vaccines against TB
Maziar Divangahi, McGill University (Canada)
Donor unrestricted T-cells (DURTS)
David Lewinsohn, Oregon Health & Science University (USA)
Tissue resident memory T-cells in infection and inflammation
Chang Ook Park, Yonsei University College of Medicine (South Korea)
Targeting checkpoint inhibitor-PD-1 for enhancing efficacy of therapeutic vaccines in tuberculosis
Dipendra K Mitra, All India Institute of Medical Sciences (India)

11:00 - 11:30

Coffee / Tea Break

11:30 - 13:00

Shahjehan

Breakout Session 3: Novel Vaccine Concepts and Preclinical Research

Details

Co-Chairs: Luciana Leite, Instituto Butantan (Brazil) | Seyed E. Hasnain, Jamia Hamdard (India)

Stress-response deficient attenuated Mycobacterium tuberculosis as next-gen TB vaccines
Deepak Kaushal, Tulane National Primate Research Center (USA)
Mechanisms of attenuation and protection of MTBVAC, a live attenuated tuberculosis vaccine moving to efficacy clinical trials
Carlos Martin, University of Zaragoza (Spain)
Increased efficacy of chemotherapy against Mycobacterium tuberculosis by additive immunotherapy using a multistage MVA vaccine
Stephane Leung-Theung-Long, Transgene (France)
Immunogenicity and efficacy evaluation of multiple ChAd3-5Ag ± MVA-5Ag prime-boost vaccine regimens in rhesus macaques
Agnes Laurence Chenine, Aeras (USA)
Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved tuberculosis protection
Matthias I. Gröschel, Institute Pasteur, Paris (France); University Medical Center Groningen (Netherlands)
Novel mucosal TB vaccine candidates generated by EMI-TB consortium
Rajko Reljic, St. George’s University of London (UK)
Presented by Gil Diogo, St. George’s University of London (UK)

Jehangir

Breakout Session 4: Biomarkers, Correlates, and Epidemiology

Details

Co-Chairs: Gerald Voss, TuBerculosis Vaccine Initiative (Belgium) | Vijaya Lakshmi Valluri, Bhagwan Mahavir Medical Research Center (India)

NK cells and memory-like NK cells as immunological markers of protection against latent TB conversion in household contacts of TB patients
Kamakshi Prudhula Devalraju, Bhagwan Mahavir Medical Research Centre (India)
Gene expression profiles of pediatric tuberculosis patients and exposed controls from India
Jeffrey A. Tornheim, Johns Hopkins University School of Medicine (USA)
Evaluating immune correlates of risk of Mycobacteria tuberculosis infection in humans
Iman Satti, University of Oxford (UK)
Maximising impact of the TB vaccine pipeline – mathematical modelling to inform target product profiles
Rebecca Claire Harris, London School of Hygiene and Tropical Medicine (UK)
Incidence of tuberculosis disease among household contacts of adult pulmonary tuberculosis patients in India – a multi centric cohort study
Sriram Selvaraju, National Institute for Research in Tuberculosis (India)
High risk for tuberculosis infections among medical and nursing trainees in India
Aarti Avinash Kinikar, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)

13:00 – 14:00

Rani Bagh Lawn

Lunch

14:00 - 16:30

Shahjehan

Plenary Session 5: Partnering for Progress and Innovation

Details

Co-Chairs/Facilitators: Ole Olesen, European & Developing Countries Clinical Trials Partnership (Netherlands) | Renu Swarup, Biotechnology Industry Research Assistance Council; Department of Biotechnology (India)

Roundtable discussion featuring:

Fareed Abdullah, South African Medical Research Council (South Africa)
Shelly Batra, Operation ASHA (India)
Michel Kazatchkine, Global Health Centre, Graduate Institute for International Development Studies (Switzerland)
Rajiv I. Modi, Chairman of the Confederation of Industry National Council on Pharmaceuticals; Cadila Pharmaceuticals (India)
Jacqueline Shea, Aeras (USA)

Closing Session

Details

Friday, 23 February 2018

Site Visits

Details

Site visits to four local institutions involved in TB research and care are offered to 5th Global Forum delegates.

8:30 – 12:00     Operation ASHA
8:30 – 14:00     Translational Health Science and Technology Institute
9:00 – 11:30      International Centre for Genetic Engineering and Biotechnology
9:30 – 13:00     National Institute for Tuberculosis and Respiratory Diseases

Click here to view the 5th Global Forum program-at-a-glance.

Click here to download the session program

Click here to download the poster program

5th Global Forum on TB Vaccines

20-23 February 2018 - New Delhi, India

Partnering for Progress and Innovation

Program

Tuesday, 20 February 2018

10:30 – 12:15

Opening Session

12:15 - 13:00

Keynote Address

13:00 – 14:00

Lunch

14:00 – 16:00

Plenary Session 1: Increasing Probability of Success and Maximizing Impact

16:15 – 17:45

Poster Discussion 1: Basic Vaccine Concepts and Correlates of Protective Immunity

Poster Discussion 2: Diagnostics and Epidemiology

Poster Viewing: Novel Vaccine Concepts; Chemistry, Manufacturing and Controls

17:45 – 18:30

Networking and Refreshments

18:30 - 20:00

Inaugural Ceremony

20:00 – 21:30

Forum Dinner

Wednesday, 21 February 2018

9:00 - 11:00

Shahjehan Plenary Session 2: Clinical Development of New TB Vaccines

11:00 - 11:30

Coffee / Tea Break

11:30 - 13:00

Breakout Session 1: Basic Science Research

Breakout Session 2: Clinical Research

13:00 – 14:00

Lunch

14:00 – 16:00

Plenary Session 3: Novel Approaches to TB Vaccine Research & Development

16:00 - 16:30

Coffee / Tea Break

16:30 – 18:00

Poster Discussion 3: Preclinical Research

Poster Discussion 4: Clinical Research and Community Engagement

Poster Viewing: Basic Science Research, Biomarkers and Correlates, Epidemiology

18:00 - 20:00

Networking Reception and Poster Viewing

Thursday, 22 February 2018

7:15 - 8:45

Satellite Session: Panel Discussion and Audience Q&A on the H4:IC31®/BCG Revaccination POI Trial Results

9:00 - 11:00

Plenary Session 4: The Cutting Edge: Translating Scientific Advances into New TB Vaccines

11:00 - 11:30

Coffee / Tea Break

11:30 - 13:00

Breakout Session 3: Novel Vaccine Concepts and Preclinical Research

Breakout Session 4: Biomarkers, Correlates, and Epidemiology

13:00 – 14:00

Lunch

14:00 - 16:30

Plenary Session 5: Partnering for Progress and Innovation

Closing Session

Friday, 23 February 2018

Site Visits

Sign up for information and updates about the Global Forum on TB Vaccines

© 2024 Stop TB Partnership/UNOPS · Privacy Policy · Terms of Use

Site by Wirebird Media